JNJ

Should Gilead Be Worried About This New Monthly HIV Medication?
Should Gilead Be Worried About This New Monthly HIV Medication?
Motley Fool
Gilead Sciences
HIV
JNJ
ViiV
cabotegravir
rilpivirine
Edurant
Flag link:
Judge Denies J&J Motion to Dismiss Pfizer Lawsuit Over Remicade
Judge Denies J&J Motion to Dismiss Pfizer Lawsuit Over Remicade
RAPS.org
Pfizer
JNJ
Remicade
biosimilars
Inflectra
Flag link:
Drug firms fight US government’s Iraq corruption probe
Drug firms fight US government’s Iraq corruption probe
Pharmaforum
Iraq
DOJ
AstraZeneca
Roche
JNJ
GE
Pfizer
Flag link:
Pharma watchers on Twitter chat up Johnson & Johnson Xarelto TV ad that seems 'misleading'
Pharma watchers on Twitter chat up Johnson & Johnson Xarelto TV ad that seems 'misleading'
Fierce Pharma
JNJ
Xarelto
drug ads
twitter
social media
Flag link:
Johnson & Johnson CEO Alex Gorsky dines with Trump as president promises ‘substantial’ drug price cuts
Johnson & Johnson CEO Alex Gorsky dines with Trump as president promises ‘substantial’ drug price cuts
Fierce Pharma
JNJ
Pharma CEOs
Alex Gorsky
Donald Trump
drug pricing
Flag link:
Pfizer Wins Remicade Patent Case Over J&J
Pfizer Wins Remicade Patent Case Over J&J
RAPS.org
Pfizer
Celltrion
JNJ
Janssen
patents
Remicade
Flag link:
BMS, Pfizer's fast-growing Eliquis is about to steamroll market-leader warfarin: executive
BMS, Pfizer's fast-growing Eliquis is about to steamroll market-leader warfarin: executive
Fierce Pharma
Pfizer
Bristol-Myers Squibb
JNJ
Eliquis
Xarelto
Warfarin
bloodthinners
Flag link:
Johnson & Johnson wins $227m DoD spinal implant supply contract
Johnson & Johnson wins $227m DoD spinal implant supply contract
Mass Device
JNJ
defense contracts
devices
spinal implants
Flag link:
Artificial hip maker demands retraction of a paper calling its research ‘grave fraudulence’
Artificial hip maker demands retraction of a paper calling its research ‘grave fraudulence’
Stat
JNJ
DePuy
Pinnacle Hip
devices
Flag link:
J&J, UPenn announce launch of Philly JLabs healthcare incubator
J&J, UPenn announce launch of Philly JLabs healthcare incubator
Mass Device
JNJ
innovation
U Penn
Philadelphia
Flag link:
[video+transcript]These 2 Healthcare Giants Had Diverging Short-Term Moves, but Have Parallel Long-Term Stories
[video+transcript]These 2 Healthcare Giants Had Diverging Short-Term Moves, but Have Parallel Long-Term Stories
Motley Fool
earnings
Unitedhealth Group
JNJ
Flag link:
Where does J&J's new drug fit in the crowded HIV market?
Where does J&J's new drug fit in the crowded HIV market?
Biopharma Dive
JNJ
Janssen
FDA
HIV
Symtuza
Flag link:
Johnson & Johnson beats revenue, profit projections for 2Q
Johnson & Johnson beats revenue, profit projections for 2Q
Yahoo/AP
JNJ
earnings
Flag link:
J&J declares a historic success as Invokana comes through in PhIII chronic kidney disease trial
J&J declares a historic success as Invokana comes through in PhIII chronic kidney disease trial
Endpoints
JNJ
Invokana
chronic kidney disease
Flag link:
J&J taps German Merck to market Invokana in China
J&J taps German Merck to market Invokana in China
Biopharma Dive
JNJ
Xian-Janssen
Merck KGaA
Invokana
China
Flag link:
Johnson & Johnson Hit by $4.7 Billion Jury Verdict in Ovarian Cancer Case
Johnson & Johnson Hit by $4.7 Billion Jury Verdict in Ovarian Cancer Case
TheStreet.com
JNJ
ovarian cancer
Flag link:
Genmab puts down $54M for immunotherapy collaboration — ready to spend millions more
Genmab puts down $54M for immunotherapy collaboration — ready to spend millions more
Endpoints
Genmab
JNJ
Europe
cancer immunotherapy
Immatics
Flag link:
J&J (JNJ) to Set Pharma Q2 Earnings in Motion: What's Up?
J&J (JNJ) to Set Pharma Q2 Earnings in Motion: What's Up?
Yahoo/Zacks.com
JNJ
earnings
Flag link:
Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's
Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's
Fierce Pharma
JNJ
Tremfya
MorphoSys
Janssen
Crohn's Disease
clinical trials
Flag link:
More than $100 Billion Spent on M&A in the First 6 Months of 2018
More than $100 Billion Spent on M&A in the First 6 Months of 2018
BioSpace
M&A
biotech
Celgene
Sanofi
Impact Biomedicines
Bioverativ
GSK
Takeda
Shire
JNJ
Flag link:

Pages